Novel Interventions for Neurodevelopmental Disorders (R21/R33)

The summary for the Novel Interventions for Neurodevelopmental Disorders (R21/R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel Interventions for Neurodevelopmental Disorders (R21/R33): Purpose. This funding opportunity announcement (FOA) solicits Exploratory/Developmental Phased Innovation (R21/R33) grant applications that propose to develop novel interventions that will improve functioning in domains commonly affected by neurodevelopmental disorders. This FOA provides support for a first phase (R21) for initial technical development and proof-of-principle and a second phase (R33) for further development, application, and evaluation of clinical utility. It is intended that the results will support the development of larger efficacy studies of the proposed novel intervention. This FOA is intended to encourage a broad scope of new treatment approaches with potential for widespread, cost-effective application across a variety of neurodevelopmental disorders based on the targeted domain(s) of impairment. The treatment approaches may include psychopharmacologic, other physiological, cognitive, psychosocial, psychoeducational, and behavioral approaches or novel combinations of any of these approaches. Also of interest are particularly innovative and theoretically-based intervention approaches currently in clinical use that have not been adequately evaluated for safety and efficacy. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental Phased Innovation (R21/R33) award mechanism and runs in parallel with an FOA of identical scientific scope, RFA-MH-09-020, which solicits applications under the R34 award mechanism. The R34 mechanism may be more appropriate when early conceptual work has been completed and proof-of-principle has been demonstrated. Funds Available and Anticipated Number of Awards. The NIMH intends to commit approximately $2,500,000 in total costs in FY09 to support four to eight awards in response to this FOA and the parallel R34 FOA. Awards under these FOAs are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Budget and Project Period. The total project period for an application submitted in response to this FOA may not exceed five years. The R21 phase may not exceed two years or $275,000 in direct costs, with no more than $150,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed three years or $450,000 in direct costs, with no more than $225,000 in direct costs in any single year of the R33 phase. Separate detailed (non-modular) budgets are required for the R21 and R33 phases. Eligible Institutions/Organizations. Institutions/organizations listed in Section III, 1.A. are eligible to apply. Eligible Project Directors/Principal Investigators (PDs/PIs): Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application. Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct. Resubmissions. Resubmission applications are not permitted in response to this FOA. Renewals. Competing renewals will not be supported under this FOA. Special Date(s). This FOA uses non-standard due dates. See Receipt, Review and Anticipated Start Dates.